Objective： The aim of this study was to analyze and compare the recent efficacy and toxicity of a three-drug platinum-based regimen （A regimen）： [cisplatin （DDP） ＋ gemcitabine （GEM） ＋ vinorelbine （NVB）] an...Objective： The aim of this study was to analyze and compare the recent efficacy and toxicity of a three-drug platinum-based regimen （A regimen）： [cisplatin （DDP） ＋ gemcitabine （GEM） ＋ vinorelbine （NVB）] and a two-drug combination without a platinum drug （B regimen）： GEM ＋ NVB, which were used to treat 55 advanced non-small cell lung cancer （NSCLC） patients, in a bid to provide a guidance for clinical treatment. Methods： Twenty-four cases of advanced NSCLC （stage Ill-IV） patients were treated with A regimen （DDP 35 mg/m^2 d1-3; GEM 1250 mg/m^2 d1, 8 ）. The other 31 cases were treated with B （GEM 1250 mg/m^2 d1,8; NVB 25 mg/m^2 d1, 8 ）. Repeat every 3 weeks for 6 courses. Results： In A regimen group, the overall response rate was 45.8% （CR ＋ PR = 11）, median response time was 5.5 months, median survival time was 11 months and 1-year survival rate was 41.7%. In B regimen group, the overall response rate was 48.4% （CR ＋ PR = 15） and median response time, survival time and 1-year survival rate were respectively 6.5 and 10 months and 41.9%. The major toxicities were nausea/vomiting, myelosuppression in A regimen group, myelosuppression and phlebitis in B regimen group, respectively. Conclusion： A regimen and B regimen for advanced NSCLC have similar response rate （P 〉 0.05）. B regimen, a two-drug combination without a platinum drug is of less toxicity and more safety than A regimen, a three-drug platinum-based regimen and is recommended to be a regimen in the first-line treatment for advanced NSCLC.展开更多
文摘Objective： The aim of this study was to analyze and compare the recent efficacy and toxicity of a three-drug platinum-based regimen （A regimen）： [cisplatin （DDP） ＋ gemcitabine （GEM） ＋ vinorelbine （NVB）] and a two-drug combination without a platinum drug （B regimen）： GEM ＋ NVB, which were used to treat 55 advanced non-small cell lung cancer （NSCLC） patients, in a bid to provide a guidance for clinical treatment. Methods： Twenty-four cases of advanced NSCLC （stage Ill-IV） patients were treated with A regimen （DDP 35 mg/m^2 d1-3; GEM 1250 mg/m^2 d1, 8 ）. The other 31 cases were treated with B （GEM 1250 mg/m^2 d1,8; NVB 25 mg/m^2 d1, 8 ）. Repeat every 3 weeks for 6 courses. Results： In A regimen group, the overall response rate was 45.8% （CR ＋ PR = 11）, median response time was 5.5 months, median survival time was 11 months and 1-year survival rate was 41.7%. In B regimen group, the overall response rate was 48.4% （CR ＋ PR = 15） and median response time, survival time and 1-year survival rate were respectively 6.5 and 10 months and 41.9%. The major toxicities were nausea/vomiting, myelosuppression in A regimen group, myelosuppression and phlebitis in B regimen group, respectively. Conclusion： A regimen and B regimen for advanced NSCLC have similar response rate （P 〉 0.05）. B regimen, a two-drug combination without a platinum drug is of less toxicity and more safety than A regimen, a three-drug platinum-based regimen and is recommended to be a regimen in the first-line treatment for advanced NSCLC.
